This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Amneal's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Amneal Pharmaceuticals.
AMRX or COLL: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMRX vs. COLL: Which Stock Is the Better Value Option?
New Strong Buy Stocks For May 26th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
AMRX or COLL: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMRX vs. COLL: Which Stock Is the Better Value Option?
Amneal (AMRX) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Amneal (AMRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Amneal's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Amneal Pharmaceuticals.
Company News for May 12, 2020
by Zacks Equity Research
Companies In The News Are:
Amneal Pharmaceuticals (AMRX) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of 150.00% and 12.50%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Amneal (AMRX) This Earnings Season?
by Zacks Equity Research
Amneal (AMRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Are Options Traders Betting on a Big Move in Amneal Pharmaceuticals (AMRX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Amneal Pharmaceuticals (AMRX) stock based on the movements in the options market lately.
Amneal (AMRX) Catches Eye: Stock Jumps 6.7%
by Zacks Equity Research
Amneal (AMRX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Amneal Pharmaceuticals (AMRX) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of 60.00% and 3.30%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
AMRX vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
AMRX vs. ZTS: Which Stock Is the Better Value Option?
Amneal Pharmaceuticals Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Amneal Pharmaceuticals
Prospects Appear Bright for Small Drug Industry in 2020
by Kinjel Shah
Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity keep small drugmakers afloat in a competitive market.
Should Value Investors Pick Amneal Pharma (AMRX) Stock Now?
by Zacks Equity Research
Let's see if Amneal Pharmaceuticals (AMRX) stock is a good choice for value-oriented investors right now from multiple angles.
AMRX vs. NBIX: Which Stock Is the Better Value Option?
by Zacks Equity Research
AMRX vs. NBIX: Which Stock Is the Better Value Option?
Company News for Dec 13, 2019
by Zacks Equity Research
Companies in the news are: FB, AMRX, LMPX, TNXP
Are Options Traders Betting on a Big Move in Amneal Pharmaceuticals (AMRX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Amneal Pharmaceuticals (AMRX) stock based on the movements in the options market lately.
Fed Reportedly Opens Criminal Investigation on Opioid Makers
by Kinjel Shah
Shares of some manufacturers and distributors of opioid drugs decline on Tuesday following reports that a criminal probe has been initiated by federal prosecutors.
Amneal Pharmaceuticals (AMRX) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of -69.23% and -4.83%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Amneal Pharmaceuticals (AMRX) Q3 Earnings Expected to Decline
by Zacks Equity Research
Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amneal Pharmaceuticals (AMRX) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of -40.00% and -6.21%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Amneal Pharmaceuticals (AMRX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ASRT or AMRX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ASRT vs. AMRX: Which Stock Is the Better Value Option?